Abstract:E3 ubiquitin ligases are a large family of proteins that can be classified into three major structurally distinct types: N-end rule E3s, E3s containing the HECT (Homology to E6AP C-Terminus) domain, and E3s with the RING (Really Interesting New Gene) finger, including its derivatives, the U- Box and the PHD (Plant Homeo-Domain). E3 ubiquitin ligases exist as single polypeptide or multimeric complexes. Together with ubiquitin activating enzyme E1 and ubiquitin conjugating enzyme E2, E3 ubiquitin ligases catalyze the ubiquitination of a variety of protein substrates for targeted degradation via the 26S proteasome. E3 ubiqutin ligases, therefore, play an essential role in regulation of many biological processes. Furthermore, E3s are enzymes that determine the specificity of protein substrates; they represent a class of “drugable” targets for pharmaceutical intervention. In this review, I will mainly focus on E3 ubiquitin ligases as potential cancer targets and discuss three of the most promising E3s, Mdm2/Hdm2, IAPs, and SCF, for their target rationales, target validation, and critical issues associated with them. These E3 ligases or their components are over-expressed in many human cancers and their inhibition leads to growth suppression or apoptosis. In addition, I will evaluate two current methodologies available for the high throughput screening for small molecular weight chemical inhibitors of the E3 ubiquitin ligases. Although targeting E3 ubiquitin ligases is still in its infancy, speedy approval of the general proteasome inhibitor, Velcade (bortezomib) by the FDA for the treatment of relapsed and refractory multiple myeloma suggests the promise of specific E3 inhibitors in anti-cancer therapy. Emerging technologies, such as siRNA, will provide a better validation of many E3s. It is anticipated that E3 ubiquitin ligases will represent an important new target platform for future mechanism-driven drug discovery.

Relationship between E3 Ubiquitin Ligase and Epithelial Cancers

E3 Ubiquitin Ligases in Cancer and Implications for Therapies

Recent Insight into the Role of RING-finger E3 Ligases in Glioma

E3 ubiquitin ligases as cancer targets and biomarkers.

Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications

The role of E3 ubiquitin ligase HECTD3 in cancer and beyond

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

The Role of Membrane-Associated E3 Ubiquitin Ligases in Cancer

Targeting E3 Ubiquitin Ligases for Cancer Therapy

Ubiquitination involved enzymes and cancer

The Molecular Basis of Ubiquitin-Conjugating Enzymes (e2s) As a Potential Target for Cancer Therapy

Ubiquitin-like proteins and hepatocellular carcinoma

E3 ubiquitin ligase HECW2: a promising target for tumour therapy

The Involvement of E3 Ubiquitin Ligases in the Development and Progression of Colorectal Cancer

Relationship of Ubiquitin-Ligases APC/C and SCF Complex to Cancer

Ubiquitin and its role in the tumor

The E2 ubiquitin-conjugating enzyme UbcH5c: an emerging target in cancer and immune disorders

Targeting the Ubiquitin Signaling Cascade in Tumor Microenvironment for Cancer Therapy

The Potential Role of Ubiquitin C-Terminal Hydrolases in Oncogenesis

Mechanism and Disease Association with a Ubiquitin Conjugating E2 Enzyme: UBE2L3

Editorial: Community series in post-translational modifications of proteins in cancer immunity and immunotherapy, volume III